对于晚期子宫内膜癌, 华和Innovent的联合药物在中国获得了条件批准. HUTCHMED and Innovent's drug combo gets conditional OK in China for advanced endometrial cancer.

华和创新生物公司宣布,他们的药物组合ELUNATE和TYVYT在中国获得了条件批准,用于治疗先进子宫内膜癌患者,这些患者有熟练的不匹配修复瘤,而之前的治疗已经失败. HUTCHMED and Innovent Biologics announced that their drug combination of ELUNATE and TYVYT has received conditional approval in China for treating advanced endometrial cancer patients with proficient Mismatch Repair tumors who have failed previous treatments. 这是第一次批准将fruquintinib与免疫检查站抑制剂相结合,其依据是第二阶段的一项研究,该研究显示了反应率和存活率的潜在好处。 This is the first approval for combining fruquintinib with an immune checkpoint inhibitor, based on a phase II study showing potential benefits in response rates and survival. 批准要求进行销售后研究,以便进一步评估。 The approval requires post-marketing studies for further evaluation.